Cadrenal Therapeutics, Inc. (CVKD) Q1 2026 Annual Earnings
CVKD·Reported May 7, 2026·Before market open
Diluted EPS came in at $-1.04 (+50.2% YoY), beat the $-1.51 consensus by $0.47.
Diluted EPS
$-1.04beat by $0.47
Consensus: $-1.51
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Cadrenal Therapeutics, Inc.'s Q1 2026 earnings report.
Cadrenal Therapeutics, Inc. (CVKD) reported Q1 2026 earnings on May 7, 2026 before market open.
Cadrenal Therapeutics, Inc. reported diluted EPS of $-1.04 for Q1 2026.
EPS beat the consensus estimate of $-1.51 by $0.47.
Compared to the same quarter a year prior, diluted EPS grew 50.2% from $-2.09.
You can read the 8-K earnings release (0001213900-26-053075) and the 10-K periodic report (0001213900-26-036946) directly on SEC EDGAR. The filing index links above go to sec.gov.